Machine-learning-derived seven-protein panel distinguishes remission from active ANCA-associated vasculitis
Confounder-aware machine-learning feature selection on plasma proteomics identified a seven-protein signature—AHSG, CLEC3B, COMP, F9, LRG1, MCAM and MRC1—to classify remission versus active ANCA-associated vasculitis (AAV). After targeted PRM mass-spectrometry assay development, a generalized linear model was evaluated in an independent cohort of 108 AAV patients and achieved AUC 0.94 (95% CI 0.90–0.98); combined discovery and validation performance was AUC 0.97. In the study cohorts, the panel outperformed routine CRP and ANCA titer measurements.
Technology: MetaDeconfoundR confounder-aware feature analysis, LASSO and Boruta feature selection, and a generalized linear model applied to targeted PRM mass-spectrometry data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: After targeted PRM mass-spectrometry assay development, a generalized linear model was evaluated in an independent cohort of 108 AAV patients and achieved AUC 0.94 (95% CI 0.90–0.98); combined discovery and validation performance was AUC 0.97.
- Still unknown: This is cross-sectional classification of disease state in patients already diagnosed with AAV, not a prospective prediction of relapse, a validated basis for stopping immunosuppression, or evidence of improved clinical outcomes. The two cohorts together included just over 200 patients with a rare disease; the authors note uncertainty from sample size and treatment heterogeneity, and the panel remains a starting point for clinical-tool development. It is an adjunct biomarker result, not proof that the seven proteins cause remission or vasculitis activity.
- AI role: Machine-learning methods accounted for clinical covariates including CRP, kidney function and ANCA-related measures, prioritized candidate plasma proteins, and reduced these to a seven-protein panel. Targeted PRM-MS quantified the selected proteins, and the GLM classified AAV remission versus active disease in an independent cohort. The measured validation performance and protein signature are the specific AI-enabled diagnostic finding.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42481524/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.